The global cerebrospinal fluid (CSF) management market size is expected to reach USD 2.31 Billion in 2030 and register a revenue CAGR of 4.8% during the forecast period. Rising number of people suffering from neurological diseases, surging demand for minimally invasive surgeries, and rapid advancements in healthcare facilities are some crucial factors expected to drive market revenue growth.
Cerebrospinal fluid is a colorless fluid found in the brain and spinal cord, which facilitates delivery of nutrients to the central nervous system of the body by removing waste products. Additionally, this fluid provides mechanical and immunological protection to the brain. Hydrocephalus is a condition where there is excess accumulation of cerebrospinal fluid inside the brain.
Request a Sample@ https://www.qyresearchmedical.com/sample/119153
Growth of the global cerebrospinal fluid (CSF) management market is being driven by increasing geriatric population prone to targeted diseases like Alzheimer’s and Parkinson’s disease. Additionally, rising awareness about hydrocephalus treatment in many developing countries is contributing significantly to revenue growth of the global market.
Market growth is also being fueled by increasing prevalence of hydrocephalus and subsequent increase in ventriculomegaly cases across the globe. Implementation of advanced sensors in cerebrospinal fluid devices due to rapid advancements in technology is improving quality of diagnosis, which is another growth supporting factor for the market. High precision devices are required for hydrocephalus treatment, as treatment of hydrocephalus is a complex process with serious complications. Implementation of new and improved sensors and telemetry devices will help improve quality and success rates of treatment procedures and thus, will play a key role in market growth. Further, modernization of the healthcare sector across the globe, particularly in developing countries, is promoting market revenue growth.
Driver: Increased prevalence of hydrocephalus
Growth of the global cerebrospinal fluid (CSF) management market is driven by factors such as high prevalence of hydrocephalus and subsequent increase in shunting procedures being performed. Hydrocephalus is common in infants and elder population. The overall prevalence of hydrocephalus is 85 per 100,000 individuals. In geriatric population, the numbers are 175 per 100,000, and more than 400 per 100,000 for population above 80 years. South America and Africa have been found to have high prevalence of this disease.
Restraint: Price volatility of raw materials
One of the biggest limitations for global market is inadequate numbers of trained neurosurgeons. There is significant shortage of trained professionals globally. With a fast-growing geriatric population, the current number of neurosurgeons is insufficient to meet demand for quality healthcare. Rising complications associated with CSF shunts and infections related to sensors are some important factors expected to restrict growth of the global cerebrospinal fluid (CSF) management market to a certain extent over the forecast period.
COVID-19 pandemic disrupted the healthcare system due to the admission of overwhelming numbers of critical patients suffering from the viral infection. This delayed other healthcare delivery, making COVID-19 treatment a priority. Further, imposition of lockdowns halted research activities and awareness programs. However, the situation has improved significantly after the pandemic. The healthcare industry has witnessed an increased influx of investment with global realization about the importance of R&D in healthcare and development of innovative devices. So with rising investment activities, CSF management market is expected to register high revenue growth.
Based on type, global cerebrospinal fluid (CSF) management market is segmented into shunts and external drainage systems. The shunts segment is expected to register robust revenue growth rate during the forecast period, which can be attributed to increasing numbers of revision shunt surgeries being performed due to shunt malfunction and infection. Shunts are useful for diverting cerebrospinal fluid away from the central nervous system (CNS) fluid compartments in a controlled manner, and also for providing an alternative pathway for fluid flow. Shunts are considered primary treatment for hydrocephalus management. Technological advancements in these devices to combat issues pertaining to biocompatibility, infection, and fouling are expected to contribute to future growth of this segment.
The external drainage system segment is expected to register rapid revenue growth rate during the forecast period. Growth of this segment can be attributed to its wide-ranging applications in monitoring CSF and related conditions. Moreover, increased research in external drainage system to address limitations associated with the existing devices is expected to augment growth of this segment.
Patient Type Insights:
Based on patient type, global cerebrospinal (CSF) fluid management market is segmented into pediatric, adult, and geriatric. Pediatric segment accounted for significant revenue share in 2021 due to rising incidence of congenital hydrocephalus and an increase in shunting procedures performed among pediatric population. In children, hydrocephalus is a common congenital condition that affects one or two babies per 1000 live births.
Several risk factors such as central nervous system infections, stroke, head injury, and tumors or lesions can affect the brain or spine and cause hydrocephalus. These conditions or risk factors are common in elderly population. So with rising elderly population across the globe, the geriatric segment accounted for significant revenue share in 2021.
Based on end-use, global cerebrospinal fluid (CSF) management market is segmented into hospitals, clinics, and others. The hospital segment accounted for largest revenue share in 2021 and is anticipated to grow at the highest rate during the forecast period, owing to a large number of in-hospital cases related to cerebrospinal fluid management in elderly population. Additionally, treatment of this disease necessitates sophisticated equipment and proper infrastructure that are generally available in hospitals. Introduction of new technologically advanced devices has enabled hospitals to treat patients with neurovascular disorders. Development of several neuro hospitals in developing countries and increased opportunities for affordable treatment are also contributing to market growth.
Based on regional analysis, cerebrospinal fluid (CSF) management market in North America is expected to account for highest revenue share over the forecast period, which can be attributed to rising geriatric population suffering from nervous disorders, along with increased approvals by the U.S. FDA for new medical products.
The Asia-Pacific market is expected to register fastest revenue growth during the forecast period. Increasing prevalence of congenital hydrocephalus in China, rising geriatric population in different countries in the region, and growing medical tourism in India and several other countries are driving market revenue growth. Increasing awareness about neurological diseases and related treatment options in the region and rising incidence of stroke are creating increased need for cerebrospinal fluid management. This will play an important role in augmenting market growth in Asia-Pacific.
Competitive landscape of the global cerebrospinal fluid (CSF) management market is consolidated with several key players operating on global and regional levels. Key players are engaged in product development and strategic alliances to expand their respective product portfolios and gain robust footing in the global market. Major players in the market include Medtronic PLC, BeckerSmith Medical Inc., Integra Lifesciences, B. Braun Melsungen, Spiegelberg GmbH & Co. KG, Sophysa S.A., Natus Medical Incorporated, Moller Medical GmbH, Delta Surgical, and DePuy Synthes.
Initiatives taken by major market players are driving growth of the global market. Some such initiatives are:
- In June 2021, CereVasc, an Auburndale-based biotech company with focus on treatment of hydrocephalus, closed its Series A round of USD 43.9 million led by ATON Partners and Perceptive Xontogeny Venture Fund. The funding will support first-in-human clinical trial of CereVasc’s eShunt System and follow-on clinical studies to support regulatory approvals.
- In April 2021, Biocept announced complete commercial launch of CNSide cerebrospinal fluid assay to address the needs of patients with metastatic brain cancer. Initially introduced in January 2021, the assays can provide a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy impacting quality of life and life expectancy.
Segments Covered in the Report
This report offers historical data and forecasts revenue growth at global, regional, and country levels, and provides an analysis of market trends in each sub-segment from 2021 to 2030. For this study, has segmented the global cerebrospinal fluid (CSF) management market on the basis of type, patient type, end-use, and region:
Cerebrospinal Fluid (CSF) Management Market Report Scope
Segments covered By Type Outlook, Patient Type Outlook, End-Use Outlook, Regional Outlook
By Type Outlook
Fixed Valve Shunts
Adjustable Valve Shunts
External Drainage Systems
External Ventricular Drainage Systems
Lumbar Drainage Systems
By Patient Type Outlook
By End-Use Outlook
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119153/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: